Member Info for BigDave13

Thks, I see where those numbers are derived from now although don’t know how Yahoo has arrived at this total, could possibly be out of date. Now that the SGS lock in has expired and they have offloaded their shares, I do not know of any other share restrictions that currently apply. I would say all 16.25bn shares are in public hands. Probably doesn’t matter too much at the moment, 13bn or 16bn, lots of shares to churn to get SP moving again.

The attached footnote to the Float number states:- A company's float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which may not be publicly traded.

@cruickie1, can you explain what the Float 13.28B refers to, how have you established this number? thks

SP moved on a £1.50 trade - oh dear, is this all we have to look forward to these days?

12-Oct-21 15:30:24 27.70 15,000 Sell* 29.00 31.00 4,155 O
12-Oct-21 15:02:57 30.00 5 Buy* 27.00 30.00 1.50

I know that the 30 day timeframe is now up but I don’t think there will be any news until the Audited Accounts are published. Part of the Restructure is subject to this event, they may need to resolve outstanding governance issues in the first instance before moving forwarding with the next phase of the transformation, imo.

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults.

If Authorized, Molnupiravir Could Be the First Oral Antiviral Medicine for the Treatment of COVID-19
Submissions to Regulatory Agencies Worldwide Underway

https://www.merck.com/news/merck-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-u-s-fda-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-c/

SGS news must be soon, worldwide requirement for oral treatment medication.

Unclejim, good post, made me chuckle. The now 3 members of the BoD have various other business interests, presumably Vela is just a part time gig for them. Awaiting NED for over 12 mths, news updates always delayed and general shareholder engagement is somewhat lacking. Let's get this deal done and we can all move on!

I will be disappointed if we get a GGP like rise. 20%, 30%, 40% just won't cut it after a 12 month wait. More like 200%, 300%, 400% for starters. Monday RNS anyone?

4 weeks tomorrow since trial results released and confirmation of commercial discussions with potential licensees. Maybe waiting for the Peer Review to be completed before any formal announcements, can't be too far away now. Global need for this type of treatment, Diabetes is only getting worse.

https://www.dailymail.co.uk/news/article-10062989/One-ten-diabetes-2030-Shock-warning-obesity-crisis-doubles-number-disease.html

A little fun survey to keep us amused til next news drops. I will keep a tally and provide a summary of responses later in the week.

If you had some spare funds, which Vela investee company would you invest in directly today that will offer the best % return by Dec 2022? State one Company only with price prediction and your reasons why (optional).

Aeristech (when it IPOs)
CODE
CSFS
KNB
MODE
MWE
RBBS

Exciting News

The Fundamentals tab has finally been updated for the first time this year. Shares in Issue and MC are now correct.

I take it as a sign of something BIG brewing, I wonder what that could be?

Green boxes working over time this morning!

Yes, at 2019 year end, SGS had a large negative fund balance covered by trade creditors and a loan of £667k. Factor in that we are now a further 21 months down the track, it is reasonable to assume that that these outstanding balances have increased. It is stated that the investor (SGS do not raise funds from the public) continued to offer support thru 2019. The Trustees may have accepted the shares on the basis that they were sold at the earliest opportunity after lock in, after all they are a charity not an II looking to be a long term investor in the market. I just see it that SGS need the monies for working capital and to repay outstanding obligations, others will have different views on this. Imo.

The recently issued SGS 2019 accounts make for interesting reading, may provide a clue as to why SGS sold their shares.

15 trading days til warrants expiration. Pump will need to commence soon or will happen naturally if commercial deal news drops this week. SP needs to hit around 0.20p for the warrant holders @ 0.15p to come out to play. At this SP level, could then in turn bring into play the 0.125p warrants. If they all go, will double Vela cash balance to c. £4.8m.

My Bad.
It is $700 per course, so $70 per pill for 2 pills per day * 5 days. Also they are looking to produce 10m courses by year end, so 100 mil pills in 3 mths.

Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government. Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to have more than 10 million courses of therapy available by the end of 2021.

Merck Who will get the pills?
The pills are meant for people who are sick with Covid but are not in the hospital. Merck’s Phase 3 clinical trial enrolled only unvaccinated people who were considered high risk, such as older people or those with medical conditions like diabetes or heart disease. Initially, the drug might only be available for those people, but experts expect it to eventually become more widely available.

The pills are designed to be taken as soon as possible once a person shows symptoms of having Covid — a time when the virus is replicating rapidly and the immune system has not yet mounted a defense. In Merck’s trial, volunteers had to have shown symptoms within the past five days, and some researchers think the pills must be taken even earlier to be most effective.

SGS finally submitted their 31/12/19 accounts at Companies House. Someone mentioned maybe one reason they sold their shares was to pay their auditors and it may actually have been the case. Next Accounts to 31/12/20 were due by yesterday! May have a read thru over the weekend and see if anything of interest to note.

@Unclejim, trial news is being closely guarded, difficult to know exactly where we are with this at the moment, what SGS/EML are doing and who they are speaking to. Still positive next next RNS is a blockbuster.
@Jimmy, yep, story just on cnbc mentioned they could be ready to supply 10m doses by year end, the market/demand is going to be huge.

Show me the money...$700 per pill.

Through the agreement, if molnupiravir receives Emergency Use Authorization (EUA) or approval by the U.S. Food and Drug Administration (FDA), Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government.

Quote from Times article reporting on Merck pill:-

On seeing the results the US Food and Drug Administration recommended stopping the trial and applying for an emergency use authorisation for the drug immediately.